AV-101 vs Esketamine (CLE-100)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

AV-101

Developed by VistaGen Therapeutics

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT02484456 · Phase 2 · completed

Nineteen participants were randomized to receive AV-101 and placebo in a double-blind crossover design. The primary clinical depression endpoint was not statistically significant at the reported time points; for example, the day-0 comparison was 20.22 with AV-101 versus 20.56 with placebo (p=0.68), and the day-13 comparison was 21.52 versus 19.69 (p=0.26).

Reported efficacy

Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 1); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 2); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 3); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 7); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 13): Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) (missed)

Result source: NCT02484456

Esketamine (CLE-100)

Developed by Clexio Biosciences

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT04103892 · Phase 2 · completed

The study randomized 146 participants overall, including 130 in the main Part B comparison, to double-blind CLE-100 or placebo alongside standard antidepressant treatment. Its clinical MADRS primary endpoint was missed: the improvement with CLE-100 was not significantly different from placebo (p=0.46), so the trial provides well-controlled but inconclusive evidence.

Reported efficacy

Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) (missed)

Result source: NCT06340958

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAV-101Esketamine (CLE-100)
MADRS, change (acute)29.7 vs 27.1+2.6 vs placebowk 1.86 · n 19NCT02484456
5 other results
  • 30.4 vs 28.6 wk 1 · n 19 · Phase 2 · secondary NCT02484456
  • 29.9 vs 30.8 wk 0.43 · n 19 · Phase 2 · secondary NCT02484456
  • 29.5 vs 29.8 wk 0.29 · n 19 · Phase 2 · secondary NCT02484456
  • 28.8 vs 28.8 wk 0.14 · n 19 · Phase 2 · secondary NCT02484456
  • 29.3 vs 29.5 wk 0 · n 19 · Phase 2 · secondary NCT02484456
-10.7 vs -9.5−1.3 vs placebowk 4.14 · n 70NCT04103892
2 other results
  • -11.7 vs -8.7 wk 4.14 · n 50 · Phase 2 · primary NCT06340958
  • -13.0 vs -7.7 wk 4.14 · n 35 · Phase 2 · secondary NCT04103892
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

AV-101
29.7 vs 27.1+2.6 vs placebowk 1.86 · n 19NCT02484456
5 other results
  • 30.4 vs 28.6 wk 1 · n 19 · Phase 2 · secondary NCT02484456
  • 29.9 vs 30.8 wk 0.43 · n 19 · Phase 2 · secondary NCT02484456
  • 29.5 vs 29.8 wk 0.29 · n 19 · Phase 2 · secondary NCT02484456
  • 28.8 vs 28.8 wk 0.14 · n 19 · Phase 2 · secondary NCT02484456
  • 29.3 vs 29.5 wk 0 · n 19 · Phase 2 · secondary NCT02484456
Esketamine (CLE-100)
-10.7 vs -9.5−1.3 vs placebowk 4.14 · n 70NCT04103892
2 other results
  • -11.7 vs -8.7 wk 4.14 · n 50 · Phase 2 · primary NCT06340958
  • -13.0 vs -7.7 wk 4.14 · n 35 · Phase 2 · secondary NCT04103892

CGI-S, change (acute)

AV-101
—Not reported
Esketamine (CLE-100)
—Not reported

MADRS response

AV-101
—Not reported
Esketamine (CLE-100)
—Not reported

MADRS remission

AV-101
—Not reported
Esketamine (CLE-100)
—Not reported

Relapse (% of patients)

AV-101
—Not reported
Esketamine (CLE-100)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. AV-101: 2 of 4 rows · Esketamine (CLE-100): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAV-101Esketamine (CLE-100)
Dropout rate
—1,080 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 1 more result
—1,440 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
7.7%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
8.3%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Discontinued due to AEs
—1,080 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 1 more result
—1,440 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
0%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
8%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Serious AEs
5.3%1,080 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 1 more result
5.3%1,440 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
0%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
2%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Most frequent reported AEs
1,080 mg for 1 Week
headache 26.3% (placebo 15.8%)
insomnia 15.8% (placebo 10.5%)
musculoskeletal pain 15.8% (placebo 15.8%)
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 1 more result
1,440 mg for 1 Week
abdominal discomfort 5.3% (placebo 10.5%)
asthenia 5.3% (placebo 0%)
cold sweat 5.3% (placebo 0%)
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
dizziness 30.8% (placebo 0%)
somnolence 15.4% (placebo 0%)
alanine aminotransferase increased 7.7% (placebo 0%)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
dizziness 13.9% (placebo 0%)
headache 12.5% (placebo 0%)
somnolence 11.1% (placebo 0%)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
dizziness 18% (placebo 4.1%)
nausea 18% (placebo 0%)
headache 12% (placebo 2%)
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

AV-101

HAM-D 20.22 vs 20.56 placebo score @ 0wk
absolute change · score
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 5 more results
20.22 vs 20.06 placebo score @ 0.14wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
20.75 vs 20.41 placebo score @ 0.29wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
19.51 vs 20.74 placebo score @ 0.43wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
21.28 vs 20.43 placebo score @ 1wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
21.52 vs 19.69 placebo score @ 1.86wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
BDI 25.35 vs 25.79 placebo score @ 0wk
absolute change · score
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 5 more results
24.76 vs 24.75 placebo score @ 0.14wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
25.88 vs 26.14 placebo score @ 0.29wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
25.64 vs 24.64 placebo score @ 0.43wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
25.82 vs 24.22 placebo score @ 1wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
25.86 vs 23.84 placebo score @ 1.86wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
HAM-A 15.71 vs 16.2 placebo score @ 0wk
absolute change · score
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 5 more results
17.3 vs 16.67 placebo score @ 0.14wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
17.83 vs 17.66 placebo score @ 0.29wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
16.48 vs 17.87 placebo score @ 0.43wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
18.42 vs 17.25 placebo score @ 1wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
18.33 vs 16.28 placebo score @ 1.86wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AV-101's landscape · Esketamine (CLE-100)'s landscape